Developmental trend of artificial blood (artificial red blood cells)

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Regarding research on artificial blood, the "Field of Artificial Blood Development" was inaugurated in 1997, supported by the Ministry of Health and Welfare Grant-in-Aid for Health Science Research, for intensive research activities in the three sub-fields, i.e., artificial red blood cells, artificial platelets, and artificial antibodies. Developed by molecular assembling technology, artificial red blood cells, in the form of hemoglobin vesicles comprising hemoglobin encapsulated with a phospholipid bilayer as a highly efficient oxygen carrier, are now under investigation in laboratory animals to verify their function and safety. These vesicles are characterized by a particle size about 1/30 that of erythrocytes, preservability in a liquid state for 2 years at room temperature, and a sufficient retention time in circulating blood without evoking activation of platelet or complements. The hemoglobin vesicles have proven both to possess a high oxygen-carrying capacity in massive exchange transfusion studies in rodents, and to be remarkably safe, based on blood biochemical tests and pathologic findings in load-dosing and repeated-dose studies. Their noticeable safety against active oxygen has also been demonstrated. A joint industry, government, and university research project on artificial red blood cells is in progress with the present objective of developing a complement to transfusion therapy for emergency lifesaving.

    Original languageEnglish
    Pages (from-to)135-139
    Number of pages5
    JournalJapan Medical Association Journal
    Volume48
    Issue number3
    Publication statusPublished - 2005 Mar

    Fingerprint

    Blood Substitutes
    Erythrocytes
    Hemoglobins
    Research
    Oxygen
    Safety
    Emergency Treatment
    Organized Financing
    Complement Activation
    Platelet Activation
    Conservation of Natural Resources
    Health
    Laboratory Animals
    Hematologic Tests
    Particle Size
    Rodentia
    Reactive Oxygen Species
    Phospholipids
    Industry
    Blood Platelets

    Keywords

    • Artificial blood
    • Artificial red blood cells
    • Function and safety evaluation
    • Hemoglobin vesicles

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Developmental trend of artificial blood (artificial red blood cells). / Takeoka, Shinji.

    In: Japan Medical Association Journal, Vol. 48, No. 3, 03.2005, p. 135-139.

    Research output: Contribution to journalArticle

    @article{a9c6105fd85a4b8e8bf4681922f256d4,
    title = "Developmental trend of artificial blood (artificial red blood cells)",
    abstract = "Regarding research on artificial blood, the {"}Field of Artificial Blood Development{"} was inaugurated in 1997, supported by the Ministry of Health and Welfare Grant-in-Aid for Health Science Research, for intensive research activities in the three sub-fields, i.e., artificial red blood cells, artificial platelets, and artificial antibodies. Developed by molecular assembling technology, artificial red blood cells, in the form of hemoglobin vesicles comprising hemoglobin encapsulated with a phospholipid bilayer as a highly efficient oxygen carrier, are now under investigation in laboratory animals to verify their function and safety. These vesicles are characterized by a particle size about 1/30 that of erythrocytes, preservability in a liquid state for 2 years at room temperature, and a sufficient retention time in circulating blood without evoking activation of platelet or complements. The hemoglobin vesicles have proven both to possess a high oxygen-carrying capacity in massive exchange transfusion studies in rodents, and to be remarkably safe, based on blood biochemical tests and pathologic findings in load-dosing and repeated-dose studies. Their noticeable safety against active oxygen has also been demonstrated. A joint industry, government, and university research project on artificial red blood cells is in progress with the present objective of developing a complement to transfusion therapy for emergency lifesaving.",
    keywords = "Artificial blood, Artificial red blood cells, Function and safety evaluation, Hemoglobin vesicles",
    author = "Shinji Takeoka",
    year = "2005",
    month = "3",
    language = "English",
    volume = "48",
    pages = "135--139",
    journal = "Asian Medical Journal",
    issn = "1346-8650",
    publisher = "Japan Medical Association",
    number = "3",

    }

    TY - JOUR

    T1 - Developmental trend of artificial blood (artificial red blood cells)

    AU - Takeoka, Shinji

    PY - 2005/3

    Y1 - 2005/3

    N2 - Regarding research on artificial blood, the "Field of Artificial Blood Development" was inaugurated in 1997, supported by the Ministry of Health and Welfare Grant-in-Aid for Health Science Research, for intensive research activities in the three sub-fields, i.e., artificial red blood cells, artificial platelets, and artificial antibodies. Developed by molecular assembling technology, artificial red blood cells, in the form of hemoglobin vesicles comprising hemoglobin encapsulated with a phospholipid bilayer as a highly efficient oxygen carrier, are now under investigation in laboratory animals to verify their function and safety. These vesicles are characterized by a particle size about 1/30 that of erythrocytes, preservability in a liquid state for 2 years at room temperature, and a sufficient retention time in circulating blood without evoking activation of platelet or complements. The hemoglobin vesicles have proven both to possess a high oxygen-carrying capacity in massive exchange transfusion studies in rodents, and to be remarkably safe, based on blood biochemical tests and pathologic findings in load-dosing and repeated-dose studies. Their noticeable safety against active oxygen has also been demonstrated. A joint industry, government, and university research project on artificial red blood cells is in progress with the present objective of developing a complement to transfusion therapy for emergency lifesaving.

    AB - Regarding research on artificial blood, the "Field of Artificial Blood Development" was inaugurated in 1997, supported by the Ministry of Health and Welfare Grant-in-Aid for Health Science Research, for intensive research activities in the three sub-fields, i.e., artificial red blood cells, artificial platelets, and artificial antibodies. Developed by molecular assembling technology, artificial red blood cells, in the form of hemoglobin vesicles comprising hemoglobin encapsulated with a phospholipid bilayer as a highly efficient oxygen carrier, are now under investigation in laboratory animals to verify their function and safety. These vesicles are characterized by a particle size about 1/30 that of erythrocytes, preservability in a liquid state for 2 years at room temperature, and a sufficient retention time in circulating blood without evoking activation of platelet or complements. The hemoglobin vesicles have proven both to possess a high oxygen-carrying capacity in massive exchange transfusion studies in rodents, and to be remarkably safe, based on blood biochemical tests and pathologic findings in load-dosing and repeated-dose studies. Their noticeable safety against active oxygen has also been demonstrated. A joint industry, government, and university research project on artificial red blood cells is in progress with the present objective of developing a complement to transfusion therapy for emergency lifesaving.

    KW - Artificial blood

    KW - Artificial red blood cells

    KW - Function and safety evaluation

    KW - Hemoglobin vesicles

    UR - http://www.scopus.com/inward/record.url?scp=20444453698&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=20444453698&partnerID=8YFLogxK

    M3 - Article

    VL - 48

    SP - 135

    EP - 139

    JO - Asian Medical Journal

    JF - Asian Medical Journal

    SN - 1346-8650

    IS - 3

    ER -